Economic information and modeling reportBudget impact modelResults
Scenario analyses
1 evidence topic · 1 source
Palovarotene budget impact analysis: CADTH scenario analyses
| Scenario | Year 1 | Year 2 | Year 3 | Three-year total |
|---|---|---|---|---|
| CADTH base case | “$4,288,612” | “$4,775,024” | “$5,272,705” | “$14,336,341” |
| Scenario 1: higher FOP prevalence (1 in 1 million) | “$7,658,235” | “$8,526,829” | “$9,415,545” | “$25,600,609” |
| Scenario 2: 100% of FOP patients are correctly diagnosed | “$4,765,124” | “$5,305,582” | “$5,858,561” | “$15,929,268” |
| Scenario 3: 100% public coverage of palovarotene | “$5,823,928” | “$6,484,589” | “$7,160,589” | “$19,469,106” |
| Scenario 4: 99% price reduction for palovarotene | “$42,886” | “$47,750” | “$52,727” | “$143,363” |